LLY · News · 20260917N
Competition and market share - weight-loss
ELI LILLY & Co · 2026-09-17 · Importance 46 · Surprise 42 · In source text
Eli Lilly and Novo Nordisk launched oral weight-loss medicines in 2026, intensifying competition in the obesity-treatment market. Novo Nordisk is reportedly leading Lilly in prescriptions to date. The broader weight-loss drug market is projected to approach $100 billion within several years, increasing the commercial stakes for Lilly’s Mounjaro, Zepbound, and oral portfolio.
Key facts
- Lilly and rival Novo Nordisk launched weight loss pills this year. source
- Eli Lilly dominates the weight loss drug market -- one set to approach $100 billion in a few years. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | contingent | — | Lilly and rival Novo Nordisk launched weight loss pills this year. |